


Amendments to the CLAIMS

independent

The following list of claims will replace all prior claims in the application:

1. (Currently amended) ~~Compounds of the general~~ A compound of formula I



wherein

W is a six-membered, non benzofused, phenyl or heteroaryl ring, substituted by V in *meta* or *para* position;

V represents -O-CH₂-CH(OCH₃)-CH₂-O-; -O-CH₂-CH(CH₃)-CH₂-O-; -O-CH₂-CH(CF₃)-CH₂-O-; -O-CH₂-C(CH₃)₂-O-; -O-C(CH₃)₂-CH₂-O-; -O-CH₂-CH(CH₃)-O-; -O-CH(CH₃)-CH₂-O-; -O-CH₂-C(CH₂CH₂)-O-; or -O-C(CH₂CH₂)-CH₂-O-;

U represents aryl; or heteroaryl;

T represents -CONR¹-; -(CH₂)_pOCO-; -(CH₂)_pN(R¹)CO-; -(CH₂)_pN(R¹)SO₂-; or -COO-;

Q represents lower alkylene; or lower alkenylene;

M represents hydrogen; cycloalkyl; aryl; heterocyclyl; or heteroaryl;

L represents -R³; -COR³; -COOR³; -CONR²R³; -SO₂R³; -SO₂NR²R³; or

-COCH(Aryl)₂;

R¹ represents hydrogen; lower alkyl; lower alkenyl; lower alkynyl; cycloalkyl; aryl; or cycloalkyl-lower alkyl;

R² and R^{2'} independently represent hydrogen; lower alkyl; lower alkenyl; cycloalkyl; or cycloalkyl-lower alkyl;

R³ represents hydrogen; lower alkyl; lower alkenyl; cycloalkyl; aryl; heteroaryl; heterocyclyl; cycloalkyl-lower alkyl; aryl-lower alkyl; heteroaryl-lower alkyl; heterocyclyl-lower alkyl; aryloxy-lower alkyl; or heteroaryloxy-lower alkyl, whereby these groups may be unsubstituted or mono-, di- or trisubstituted with hydroxy, -OCOR², -COOR², lower alkoxy, cyano, -CONR²R^{2'}, -CO-morpholin-4-yl, -CO-((4-loweralkyl)piperazin-1-yl), -NH(NH)NH₂, -NR⁴R^{4'} or lower alkyl, with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp³-hybridized;

R⁴ and R^{4'} independently ~~represents~~ represent hydrogen; lower alkyl; cycloalkyl; cycloalkyl-lower alkyl; hydroxy-lower alkyl; -COOR²; or -CONH₂;

k is the integer 0 or 1;

m and n represent the integer 0 or 1, with the proviso that in case m represents the integer 1, n is the integer 0, ~~and~~ in case n represents the integer 1, m is the integer 0; and in case k represents the integer 0, n represents the integer 0; and

p is the integer 1, 2, 3 or 4;

[[and]] or optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; ~~as well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

2. (Currently amended) ~~Compounds of general~~ The compound of formula I according to claim 1, wherein ~~W, V, U, T, Q, L, and M are as defined in general formula I and~~

k is 1;

n is 0; and

m is 1,

[[and]] or optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; as ~~well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

3. (Currently amended) ~~Compounds of general~~ The compound of formula I according to claim 1, wherein ~~W, V, U, T, Q, M, k, m, and n are as defined in general formula I and~~

L represents -COR^{3''}; -COOR^{3''}; or -CONR^{2''}R^{3''}; and

R^{2''} and R^{3''} represent independently lower alkyl; lower cycloalkyl-lower alkyl, which lower alkyl and lower cycloalkyl-lower alkyl are undubstituted or mono-substituted with halogen, -CN, -OH, -OCOCH₃, -CONH₂, -COOH, or -NH₂, with the proviso that a carbon atom is attached at the most to one heteroatom in case this carbon atom is sp³-hybridized,

[[and]] optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; as ~~well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

4. (Currently amended) ~~Compounds of general~~ The compound of formula I according to claim 1, wherein ~~W, V, U, L, k, m, and n are as defined in general formula I and~~

T represents -CONR¹-;

Q represents methylene; and

M represents aryl, or heteroaryl;

[[and]] or optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, ~~mixtures of diastereomeric racemates, [[and]]~~ or the meso-form of the compound; as ~~well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

5. (Currently amended) ~~Compounds of general~~ The compound of formula I according to claim 1, wherein ~~W, U, L, T, Q, M, k, m, and n are as defined in general formula I and~~

V represents -O-CH₂-CH(CH₃)-CH₂-O-; or -O-CH₂-C(CH₃)₂-CH₂-O-;

[[and]] or optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; as ~~well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

6. (Currently amended) ~~Compounds of general~~ The compound of formula I according to claim 1, wherein ~~V, U, T, Q, M, L, k, m, and n are as defined in general formula I and~~

W represents a 1,4-disubstituted phenyl ring,

[[and]] or optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; as ~~well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

7. (Currently amended) ~~Compounds of general~~ The compound of formula I according to claim 1, wherein W, V, Q, T, M, L, m, and n are as defined in ~~general formula I and~~

U is a mono-, di-, or trisubstituted phenyl or heteroaryl, whereby the substituents are selected from the group consisting of halogen, lower alkyl, lower alkoxy, and CF₃

[[and]] optically pure enantiomers, ~~mixtures of enantiomers such as~~ racemates, diastereomers, mixtures of diastereomers, diastereomeric racemates, mixtures of diastereomeric racemates, [[and]] or the meso-form of the compound; as ~~well as~~ or pharmaceutically acceptable salts, solvent complexes [[and]] or morphological forms of the compound.

8. (Currently amended) ~~The compounds~~ compound according to ~~any one of claims 1 to 7~~ claim 1 selected from the group consisting of:

(1R, 5S)-7-{4-[(2S)-2-methyl-3-(2,3,6-trifluorophenoxy)propoxy]-phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichloro-benzyl)amide;

(1S, 5R)-7-{4-[(2S)-2-methyl-3-(2,3,6-trifluoro-phenoxy)propoxy]phenyl}-3,9-iazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichloro-benzyl)amide;
and

a mixture of (1R, 5S)-7-{4-[(2S)-2-methyl-3-(2,3,6-trifluorophenoxy)propoxy]-phenyl}-3,9-diazabicyclo[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide and (1S, 5R)-7-{4-[(2S)-2-methyl-3-(2,3,6-trifluoro-

phenoxy)propoxy]phenyl)-3,9-diazabicyclo-[3.3.1]non-6-ene-6-carboxylic acid cyclopropyl-(2,3-dichlorobenzyl)amide.

9. (Currently amended) ~~Pharmaceutical compositions containing A~~
pharmaceutical composition comprising at least one compound of ~~any ones of claims 1 to 8~~ claim 1 and ~~usual carrier materials and adjuvants for the treatment or prophylaxis of disorders which are associated with a dysregulation of the renin-angiotensin system (RAS), comprising cardiovascular and renal diseases, hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, complications of treatment with immunosuppressive agents after organ transplantation, and other diseases known to be related to the RAS~~ a carrier and/or an adjuvant.

10. (Currently amended) A method for the treatment or prophylaxis of ~~diseases which are related to the RAS~~ RAS-associated diseases comprising hypertension, congestive heart failure, pulmonary hypertension, cardiac insufficiency, renal insufficiency, renal or myocardial ischemia, atherosclerosis, renal failure, erectile dysfunction, glomerulonephritis, renal colic, glaucoma, diabetic complications, complications after vascular or cardiac surgery, restenosis, or complications of treatment with immunosuppressive agents after organ transplantation, ~~and other diseases which are related to the RAS,~~ which method comprises administering a compound according to ~~any one of claims 1 to 8~~ claim 1 to a human being or animal.

11. (Cancelled).

12. (Cancelled).